Babraham Bioscience Technologies Limited
Babraham Bioscience Technologies Ltd (BBT) is responsible for the commercial development of the Babraham Research Campus. The Babraham Research Campus is distinct in its co-location of bioscience companies with the Babraham Institute, a world-renowned research organisation. The Campus provides companies laboratory and office space together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.
|Address:||Babraham Research Campus, Babraham, Cambridge|
|Membership type:||Corporate 51+ (£1,000+VAT pa)|
The Babraham Research Campus is considered to be the UK’s leading campus to support early-stage bioscience enterprise and is distinct in its co-location of bioscience companies with the Babraham Institute, a world-renowned research organisation. The Campus provides companies with state-of the-art laboratory and office space together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.
Book your Exclusive Christmas Party from £22.50pp.
29 October 2018Read in full
Babraham is offering FREE half day* meeting room hire deals throughout August in The Cambridge Building, when booking the Abbey Delegate Package.
2 August 2018Read in full
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced that it has been awarded a grant from Innovate UK, the UK’s innovation agency, to apply Bicycle technology to develop the next generation of novel antibiotics.
8 January 2018Read in full
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has entered into an agreement with Babraham Bioscience Technologies Limited, (BBT) the company that manages and develops the Babraham Research Campus, to run and develop the services formerly provided by BBT’s Technology Development Laboratory (TDL).
5 January 2018Read in full
Mission Therapeutics, a Babraham-based drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat serious diseases including mitochondrial diseases, neurodegeneration, inflammation and cancer, today announced the formation of its inaugural Scientific Advisory Board (SAB).
27 June 2017Read in full
Madrid, Spain, Heidelberg, Germany, and Cambridge, UK...Innova Biosciences (Innova), a specialist provider of bioconjugation products and services, has announced it has been fully acquired by SYGNIS AG, for EUR 8 million in cash and 3.5 million in shares.
26 June 2017Read in full
Held at The Babraham Research Campus, the annual Babraham Investor Conference (BIC) gave scale-up and venture-stage growth companies seeking Seed to Series C funding, the opportunity to showcase their science to investors actively seeking further investment opportunities.
26 May 2017Read in full
Innova Biosciences, a specialist provider of bioconjugation products and services, today announced it has added ALEXA Fluor® 488, one of the most popular fluorescent labels used by life science researchers, to its Lightning-Link® range of antibody and protein labeling kits.
4 May 2017Read in full
Today, the Biotechnology and Biological Sciences Research Council (BBSRC), Babraham Bioscience Technologies Ltd (BBT) and BioMed Realty, a Blackstone portfolio company, have announced a partnership that will see BioMed Realty signing a long-term lease on approximately eight acres of BBSRC-owned land at the Babraham Research Campus, Cambridge. The investment will enable the ground-up construction of two new buildings for growing bioscience-based companies at the campus.
19 April 2017Read in full